°â»ó ÀûÇ÷±¸ ºóÇ÷ °Ë»ç ¹× ¼±º° °Ë»ç ½ÃÀå :±â¼ú, ¿¬·ÉÃþ, ¼½Åͺ° - ¼¼°è ¿¹Ãø(2025-2030³â)
Sickle Cell Anemia Testing & Screening Market by Technology (Hemoglobin Electrophoresis, High-performance Liquid Chromatography, Point-of-Care Tests), Age Group, Sector - Global Forecast 2025-2030
»óǰÄÚµå : 1601323
¸®¼­Ä¡»ç : 360iResearch Private Limited
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 195 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,939 £Ü 5,561,000
PDF, Excel & 1 Year Online Access (Single User License) help
PDF ¹× Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 4,249 £Ü 5,999,000
PDF, Excel & 1 Year Online Access (2-5 User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿Àϱâ¾÷ ³» 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 5,759 £Ü 8,131,000
PDF, Excel & 1 Year Online Access (Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ Áö¿ª »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 6,969 £Ü 9,840,000
PDF, Excel & 1 Year Online Access (Enterprise User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

°â»ó ÀûÇ÷±¸ ºóÇ÷ °Ë»ç ¹× ¼±º° °Ë»ç ½ÃÀåÀº 2023³â¿¡ 9¾ï 4,395¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 10¾ï 7,069¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 13.51%·Î ¼ºÀåÇϰí 2030³â¿¡´Â 22¾ï 9,322¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

°â»ó ÀûÇ÷±¸ ºóÇ÷ÀÇ °Ë»ç ¹× ½ºÅ©¸®´×¿¡´Â ÁÖ·Î Çì¸ð±Û·Îºó Àü±â¿µµ¿, °í¼Ó ¾×ü Å©·Î¸¶Åä±×·¡ÇÇ(HPLC), À¯ÀüÀÚ °Ë»ç µîÀÇ Ç÷¾× °Ë»ç¸¦ ÅëÇÑ °â»ó ÀûÇ÷±¸Áõ(S CD)¿Í °â»ó ÀûÇ÷±¸ ÇüÁú(SCT)À» È®ÀÎÇϱâÀ§ÇÑ ´Ù¾çÇÑ Áø´Ü ±â¼úÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. ÇÕº´ÁõÀ» ¿¹¹æÇϱâ À§ÇÑ Á¶±â Áø´ÜÀÇ Çʿ伺¿¡ ÀÇÇØ °­Á¶µÇ¾î, ȯÀÚÀÇ °á°ú¿Í »ýȰÀÇ ÁúÀÌ °³¼±µË´Ï´Ù.ÀÇ ÀÏ»óÀûÀÎ ¸ð´ÏÅ͸µ±îÁö È®Àå.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 9¾ï 4,395¸¸ ´Þ·¯
¿¹Ãø³â(2024) 10¾ï 7,069¸¸ ´Þ·¯
¿¹Ãø³â(2030) 22¾ï 9,322¸¸ ´Þ·¯
CAGR(%) 13.51%

½ÃÀå ¼ºÀåÀº À¯Àü¼º Áúȯ¿¡ ´ëÇÑ ÀνÄÀÌ Áõ°¡ÇÏ°í ½Å»ý¾Æ ½ºÅ©¸®´× ÇÁ·Î±×·¥¿¡ ´ëÇÑ Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê, À¯ÀüÀÚ °Ë»çÀÇ ±â¼ú Áøº¸ µîÀÇ ¿äÀο¡ ¿µÇâÀ» ¹Þ½À´Ï´Ù. ÅõÀÚ Áõ°¡·Î ÀÎÇØ ºñÁî´Ï½º ±âȸ°¡ Ä¿Áö°í ÀÖ½À´Ï´Ù. ±â¾÷¿¡ ´ëÇÑ Á¶»ç´Â ÆÄÆ®³Ê½ÊÀ» ÅëÇÑ Áö¸®Àû Á¸ÀçÀÇ È®´ë, ºñ ħ½ÀÀû °Ë»ç¹ý ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ, ÀÎÁöµµ Çâ»óÀ»À§ÇÑ ¾Æ¿ô¸®Ä¡ ÇÁ·Î±×·¥ °­È­ µîÀ» Æ÷ÇÔÇÕ´Ï´Ù. µË´Ï´Ù.

±×·¯³ª Àú¼Òµæ Áö¿ªÀÇ °Ç°­ °ü¸® ½Ã¼³¿¡ ´ëÇÑ Á¢±Ù Á¦ÇÑ, °íµµ Áø´Ü ±â¼ú ºñ¿ë ¹× ÈÆ·Ã µÈ Àü¹®°¡ ºÎÁ·°ú °°Àº ¹®Á¦¿¡ Á÷¸é ÇØ ÀÖ½À´Ï´Ù. ¹æÇØ À̸¦ ±Øº¹Çϱâ À§ÇØ Çõ½ÅÀûÀÎ ºÐ¾ß·Î¼­ ºñ¿ë È¿À²ÀûÀ̰í ÈÞ´ë °¡´ÉÇÑ °Ë»ç ¼Ö·ç¼ÇÀÇ °³¹ß°ú ¿ø°ÝÁö »ç¶÷µé¿¡°Ô ¼­ºñ½º¸¦ Á¦°øÇÏ´Â ¿ø°Ý ÀÇ·á ¼­ºñ½º °³¼± µîÀ» µé ¼ö ÀÖ½À´Ï´Ù.

¿¬±¸ÀÇ ¹æÇ⼺Àº À¯ÀüÀÚ Áø´Ü°ú ºÐÀÚÁø´Ü¿¡ ÃÊÁ¡À» ¸ÂÃß°í CRISPR ±â¼úÀ» °áÁ¤ÀûÀÎ °Ë»ç¿¡ Àû¿ëÇÏ´Â °Íµµ »ý°¢ÇÒ ¼ö ÀÖ½À´Ï´Ù. ½ÃÀå ºÐ¼®ÀÌ ÇʼöÀûÀÔ´Ï´Ù. ±Þ¼ÓÇÑ ±â¼ú Çõ½Å°ú Áö¿ª¿¡ µû¶ó ´Ù¸¥ °Ç°­ ÄÉ¾î ´É·ÂÀ» Ư¡À¸·Î ÇÏ´Â ÀÌ ½ÃÀå¿¡¼­´Â ¼ºÀå ±âȸ¸¦ Ȱ¿ëÇϸ鼭 ÀÌ·¯ÇÑ °úÁ¦¿¡ ´ëóÇϱâ À§ÇÑ ¹ÎøÇÑ »ç¾÷ Àü·«ÀÌ ¿ä±¸µË´Ï´Ù. Çù·Â, ÀûÀÀ °¡´ÉÇÑ Á¦Ç° °³¹ß¿¡ ÅõÀÚÇØ¾ßÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ: ±Þ¼ÓÈ÷ ÁøÈ­ÇÏ´Â °â»ó ÀûÇ÷±¸ ºóÇ÷°Ë»ç ¹× ¼±º° °Ë»ç ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

°â»ó ÀûÇ÷±¸ ºóÇ÷ °Ë»ç ¹× ¼±º° °Ë»ç ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ðÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÅõÀÚ°áÁ¤, Àü·«Àû °áÁ¤ Á¤¹ÐÈ­, »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæ¿¡ ´ëºñÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦ÀûÀÎ ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ½°ú µ¿½Ã¿¡, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ëÀ̳ª ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

Porter's Five Forces °â»ó ÀûÇ÷±¸ ºóÇ÷ °Ë»ç ¹× ¼±º° °Ë»ç ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ±â¹ýÀ» Á¦°øÇÕ´Ï´Ù. ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ´ç½ÅÀº ´õ °­ÀÎÇÑ ½ÃÀå¿¡¼­ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : °â»ó ÀûÇ÷±¸ ºóÇ÷ °Ë»ç ¹× ¼±º° °Ë»ç ½ÃÀå¿¡¼­ ¿ÜºÎ ¿µÇâÀ» ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº °â»ó ÀûÇ÷±¸ ºóÇ÷ °Ë»ç ¹× ¼±º° °Ë»ç ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸ À» Á¦°øÇÕ´Ï´Ù.PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×¸®°í ¾ÕÀ» ³»´Ùº¸°í Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ°¡ µË´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® °â»ó ÀûÇ÷±¸ ºóÇ÷ °Ë»ç ¹× ¼±º° °Ë»ç ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

°â»ó ÀûÇ÷±¸ ºóÇ÷ °Ë»ç ¹× ¼±º° °Ë»ç ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. °æÀïÀû Æ÷Áö¼Å´× À̸¦ ÅëÇØ ½ÃÀåÀÇ ÁýÁß, ´ÜÆíÈ­, ÅëÇÕÀÇ µ¿ÇâÀ» ¹àÇô³»°í, º¥´õ´Â °æÀïÀÌ °ÝÈ­ÇÏ´Â °¡¿îµ¥ ÀÚ½ÅÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«ÀûÀÎ ÀÇ»ç°áÁ¤À» Çϱâ À§ÇØ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¹× ¸ÅÆ®¸¯½º °â»ó ÀûÇ÷±¸ ºóÇ÷ °Ë»ç ¹× ¼±º° °Ë»ç ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Positioning Matrix´Â °â»ó ÀûÇ÷±¸ ºóÇ÷ °Ë»ç ¹× ¼±º° °Ë»ç ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Æò°¡¸¦ ÅëÇØ ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ: ¾÷°è ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅ͸¦ Æ÷ÇÔÇÑ ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­: ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

Á¦6Àå °â»ó ÀûÇ÷±¸ ºóÇ÷ °Ë»ç ¹× ¼±º° °Ë»ç ½ÃÀå : ±â¼úº°

Á¦7Àå °â»ó ÀûÇ÷±¸ ºóÇ÷ °Ë»ç ¹× ¼±º° °Ë»ç ½ÃÀå : ¿¬·ÉÃþº°

Á¦8Àå °â»ó ÀûÇ÷±¸ ºóÇ÷ °Ë»ç ¹× ¼±º° °Ë»ç ½ÃÀå : ¼½Åͺ°

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ °â»ó ÀûÇ÷±¸ ºóÇ÷ °Ë»ç ¹× ¼±º° °Ë»ç ½ÃÀå

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °â»ó ÀûÇ÷±¸ ºóÇ÷ °Ë»ç ¹× ¼±º° °Ë»ç ½ÃÀå

Á¦11Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ °â»ó ÀûÇ÷±¸ ºóÇ÷ °Ë»ç ¹× ¼±º° °Ë»ç ½ÃÀå

Á¦12Àå °æÀï ±¸µµ

±â¾÷ ¸ñ·Ï

BJH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Sickle Cell Anemia Testing & Screening Market was valued at USD 943.95 million in 2023, expected to reach USD 1,070.69 million in 2024, and is projected to grow at a CAGR of 13.51%, to USD 2,293.22 million by 2030.

Sickle Cell Anemia Testing and Screening encompasses a range of diagnostic techniques aimed at identifying sickle cell disease (SCD) and sickle cell trait (SCT), primarily through blood tests such as hemoglobin electrophoresis, high-performance liquid chromatography (HPLC), and genetic testing. The necessity of these tests is underscored by the need for early diagnosis to prevent severe complications like pain crises, stroke, and organ damage, thus improving patient outcomes and quality of life. Applications extend from prenatal screening to newborn and carrier testing and routine monitoring for individuals at risk. The end-use scope includes healthcare facilities, research institutions, and diagnostic laboratories that require precise and rapid diagnostic capabilities.

KEY MARKET STATISTICS
Base Year [2023] USD 943.95 million
Estimated Year [2024] USD 1,070.69 million
Forecast Year [2030] USD 2,293.22 million
CAGR (%) 13.51%

Market growth is influenced by factors such as increased awareness of genetic disorders, government initiatives for newborn screening programs, and technological advancements in genetic testing. Emerging markets in Asia-Pacific and Africa present substantial opportunities due to high prevalence rates and increasing healthcare infrastructure investments. Recommendations for businesses include expanding geographic presence through partnerships, investing in research for non-invasive testing methods, and enhancing outreach programs to raise awareness.

However, market growth faces challenges such as limited access to healthcare facilities in low-income regions, high costs of advanced diagnostic technologies, and lack of trained professionals. Regulatory hurdles can also impede the swift introduction of new testing methods. To overcome these, innovation areas include developing cost-effective, portable testing solutions and improving telehealth services to reach remote populations.

Research directions could focus on genetic and molecular diagnostics, exploring CRISPR technology for definitive tests. Continuous market analytics is crucial to adapt to changing regulatory landscapes and patient needs. The market, characterized by rapid technological change and varying regional healthcare capabilities, requires agile business strategies to address these challenges while capitalizing on growth opportunities. This dynamic environment calls for companies to invest in education campaigns, stakeholder collaborations, and adaptive product development.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Sickle Cell Anemia Testing & Screening Market

The Sickle Cell Anemia Testing & Screening Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Porter's Five Forces: A Strategic Tool for Navigating the Sickle Cell Anemia Testing & Screening Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Sickle Cell Anemia Testing & Screening Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Sickle Cell Anemia Testing & Screening Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Sickle Cell Anemia Testing & Screening Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Sickle Cell Anemia Testing & Screening Market

A detailed market share analysis in the Sickle Cell Anemia Testing & Screening Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Sickle Cell Anemia Testing & Screening Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Sickle Cell Anemia Testing & Screening Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Sickle Cell Anemia Testing & Screening Market, highlighting leading vendors and their innovative profiles. These include Biomedomics Inc., HiMedia Laboratories, Pfizer Inc., Silver Lake Research Corporation, Thermo Fisher Scientific Inc., Vertex Pharmaceuticals Incorporated, Edvotek Inc., Atlas Medical GmbH, Hemex Health, Quest Diagnostics Incorporated, CRISPR Therapeutics AG, Anamol Laboratories Pvt. Ltd., Ulta Lab Tests, LLC, Bio-Rad Laboratories, Inc., Bio Lab Diagnostics (I) Private Limited, PerkinElmer, Inc., Bluebird bio, Inc., Streck, Inc., Maternova Inc., Laboratory Corporation of America Holdings, Calibre Scientific, Inc., PicnicHealth, and Agios Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Sickle Cell Anemia Testing & Screening Market to forecast the revenues and analyze trends in each of the following sub-markets:

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

6. Sickle Cell Anemia Testing & Screening Market, by Technology

7. Sickle Cell Anemia Testing & Screening Market, by Age Group

8. Sickle Cell Anemia Testing & Screening Market, by Sector

9. Americas Sickle Cell Anemia Testing & Screening Market

10. Asia-Pacific Sickle Cell Anemia Testing & Screening Market

11. Europe, Middle East & Africa Sickle Cell Anemia Testing & Screening Market

12. Competitive Landscape

Companies Mentioned

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â